PHARMAMAR HA OPTADO POR LA RETIRADA DE LA SOLICITUD DE AUTORIZACIÓN DE COMERCIALIZACIÓN DE APLIDIN ( PLITIDEPSIN ) ... WITHDRAWAL OF APPLICATIÓN FOR THE MARKETING AUTHORISATION OF APLIDIN ( PLITIDEPSIN ) JULY 23 , 2025 .
Trabectedin (Yondelis®). This drug binds to DNA and interacts with DNA repair enzymes to disrupt the cell cycle. It has demonstrated good clinical activity in Phase III trials of patients with ovarian cancer.